Faes Farma 9M 2026 Operating Profit Rises 7% to EUR 94.48 Million
Bitget2026/10/29 07:11- Faes Farma’s consolidated profit for the first nine months of 2026 rose to €74.28 million.
- Revenue climbed 24% to €563.54 million, driven by acquisitions and strong international growth.
- Bilastine licence revenue fell 23% to €59 million due to generic competition in Japan.
- The integration of SIFI and Edol remained on schedule, with ophthalmology revenue reaching €96.8 million.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Bank of Japan minutes turn hawkish: Most members believe a rate hike is needed soon, with a 70% probability of a hike in December
Minutes from the Bank of Japan show that several members believe a rate hike is needed in the near term, with a roughly 70% probability of an increase in December. Core inflation has met the target for the first time in 30 years, and the current policy rate stands at 1.25%.
Former Chainlink Product Marketing Director Michael Robinson joins Monad Foundation
The Federal Reserve Eyes $1.8 Trillion in “Shadow Credit”: Dallas and New York Fed Launch First Private Credit Survey
The Dallas and New York Federal Reserves have launched an investigation into private credit lending standards, covering an industry worth 1.8 trillions USD, with a minimum threshold of 50 millions USD. The results will be released in the first quarter of 2027.
Tom Lee Says a VIX Signal Points to a Stock Market Bottom
Crypto prices
More
